Casirivimab/imdevimab vs usual care: Mortality by day 30
- Population
- hospitalised individuals with COVID‐19 (moderate to severe disease)
- Intervention
- Casirivimab/imdevimab
- Comparison
- usual care
- Outcome
- Mortality by day 30
Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Casirivimab/imdevimab vs usual care alone Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty). SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane Headline outcomes only | RR 0.94 [0.87, 1.02] | 1 study · 9785 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Casirivimab/imdevimab vs placebo · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.